PEOPLE - Focal (US) makes appointment:
This article was originally published in Clinica
Executive Summary
US surgical sealant company Focal has appointed Robert DePasqua president, CEO and member of the board. Mr DePasqua, a former CEO of Biolink and Spectranetics, replaces interim president and CEO, Donald Grilli, who takes on the new role of chairman. Focal's previous president and CEO, David Clapper, resigned late last year due to a chronic family medical condition.
You may also be interested in...
Common Regulatory Starting Point Means EU-UK Are On Track For Medtech MRA, Say German Firms
With Brexit less than a month old, Germany’s medtech industry has renewed its push for an MRA between the EU and UK in medtech regulation.
COVID-19 Vaccines Donated To Philippines Require Emergency Use Authorization
Days after a senior Chinese government official offered free COVID-19 vaccines to the Philippines government, the country’s medicines regulator said the donated jabs would need an emergency approval before they can be used on the public.
Purespring Therapeutics: Pioneering Gene Therapy For Kidney Disorders
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: